Healthcare
Polyrizon Ltd.(PLRZ)
Live Price
Offline$13.42
+1.44% today
1Y Change
+315.74%
Window
Jun 23, 2025 โ May 29, 2026
- Market Cap
- $20.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +98.5%
- Dividend Yield
- 0.0%
Coverage: 236 bars ยท Jun 23, 2025 โ May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Polyrizon Ltd. (PLRZ) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $13.42 and up 315.7% across the available one-year price window (Jun 23, 2025 โ May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +98.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +98.5%, free cash flow -295.4% with operating margin 0.0% and ROIC -17.9%. Stock Foundry combines PLRZ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 25, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +98.5%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PLRZ
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PLRZ Max Drawdown
-72.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PLRZ and SPY.
Company Overview
Polyrizon Ltd.
NASDAQ Global Market
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
- Leadership
- Tomer Izraeli
- IPO Date
- Oct 29, 2024
- Employees
- 2
- Street Address
- 5 Ha-Tidhar Street
- Mailing
- Ra'anana, 4366507
- Region
- Ra'anana, IL
- Reporting Currency
- USD
- Investor Line
- 972 9 374 0120
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.2
Growth
- Revenue
- 0.0%
- EPS
- +98.5%
- Free Cash Flow
- -295.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -26.1%
- ROIC
- -17.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 29.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.